ADC药物备受关注，关注恒生生物科技ETF国泰（520933）投资价值

Core Viewpoint - ADC drugs are gaining global attention as a new generation of precision anti-cancer biopharmaceuticals, with 21 approved and 4 under application for market entry, alongside over 1900 research projects, of which approximately 500 are in clinical stages [1] Industry Overview - The ADC drug market is characterized by active trading, but it faces multiple challenges such as drug resistance and low endocytosis efficiency [1] - Chinese companies have made significant progress in payload iteration and improving internalization efficiency, with firms like Innovent Biologics leading globally [1]